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Human Papillomavirus Vaccination at a 
Time of Changing Sexual Behavior 
Technical Appendix 
Additional Details Regarding Methods and Results 
Transmission model description 
The transmission model used to simulate the transmission and natural history of 
HPV16 infection and to project the impact of vaccination has been extensively described and 
validated elsewhere (3). Briefly, we developed a partial integro-differential equation model of 
heterosexually transmitted HPV infection. HPV16 was modeled independently from the other 
types. The model accounted for the effect of several time scales: calendar, age, and time since 
infection (as a determinant of infection clearance). 
To estimates the values of HPV16 biologic parameters (i.e., probability of infection 
transmission per sexual partnership, rate of clearance by duration since infection, and fraction 
of immunity after infection clearance), we separately fitted the model’s outputs to the HPV16 
and age-specific prevalence curves observed in large population-based studies from Italy and 
Sweden. For both countries, information on sexual behavior was collected from nationwide 
population-based surveys and applied to study populations. 
We represented the network of sexual partnerships by making some simplifications 
about contact patterns within the 2 populations: a) all sexual contacts were heterosexual; b) 
concurrent sexual partnerships were not explicitly accounted for; c) the annual rate of 
acquisition of new sexual partners varied only by age-group (5-year age-groups ranging 
between 14 and 75 years) and class of sexual activity; and d) sexual preferences were 
represented in terms of age and sexual activity assortativeness (i.e., the tendency of persons 
with similar age and sexual activity to form sexual partnerships). 
Finally, the estimation process for parameters was conceived as 2 independent sets of 
simulations that were blind to the other’s outputs and used the same transmission model and 
methodology. We assessed the validity of estimates by cross- and out-of-sample validation 
tests. 
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Model-Based Analyses 
Recent data from school- and community-based vaccination programs in medium- 
and low-income countries show that a 3-dose vaccination coverage of young girls can range 
between 70% and >90% (4,5). In our model analyses, vaccination coverage was 
conservatively assumed to be 70% for 11-year-old adolescent girls, with a 95% vaccine 
efficacy against HPV16 on the basis of reported vaccine trials. Lifelong immunity is the 
current expected duration of vaccine-induced immunity (6). 
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Technical Appendix Table 1. Assumed relative annual rates of new sexual partners by gender, age, and level of sexual 
activity in populations with traditional or gender-similar age-specific sexual behavior* 
Characteristic 
Type of Sexual Behavior 
Traditional Gender similar 
Age Men Women Both genders 
 <20 2 4 10 
 20–24 2 8 15 
 25–29 1 4 3 
 30–34 1 4 3 
 35–39 1 2 2 
 40–44 1 2 2 
 45–49 1 1 1 
 >50 1 1 1 
Level of sexual activity†    
 Low 1 1 1 
 High 5 5 5 
*Rates were assumed and imposed on our model and are relative because they are multiplicative factors (as relative risks), a method used in the 
literature (7,8) to represent age-specific patterns of rates of sexual activity. 
†“High” and” low” are standard denominations for classes of sexual activity and indicate classes of sexual activity with a higher and lower number of 
partners. 
 
Technical Appendix Table 2. Average annual number of new sexual partners by gender, age, and level of sexual activity in 
populations with traditional and gender-similar age-specific sexual behavior* 
Age 
Traditional Gender similar 
Men Women Both genders 
Level of sexual activity 
Low High Low High Low High 
15 0.59 2.96 0.46 2.28 0.60 3.00 
20 1.78 8.89 1.64 8.21 1.98 9.91 
25 1.60 8.00 2.46 12.31 2.27 11.35 
30 0.89 4.44 1.37 6.84 0.54 2.70 
35 0.89 4.44 1.23 6.15 0.50 2.52 
40 0.89 4.44 0.68 3.42 0.36 1.80 
45 0.89 4.44 0.62 3.08 0.32 1.62 
50 0.89 4.44 0.34 1.71 0.18 0.90 
55 0.89 4.44 0.34 1.71 0.18 0.90 
60 0.89 4.44 0.34 1.71 0.18 0.90 
*Reported average annual numbers of new sexual partners were obtained by assuming and imposing on the model a set of relative rates of sexual 
activity (Technical Appendix Table 1) and allowing the average number of new sexual partners per year to vary between 1–2 in the calibration 
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Technical Appendix Table 3. Relative reduction in HPV16 prevalence attributable to vaccination, by number of years since 





Age at catch-up† 
vaccination 
Reduced prevalence for traditional sexual 
behavior, % 
Reduced prevalence for gender-similar 
sexual behavior, % 
No catch-up 
Catch-up age range 
No catch-up 
Catch-up age range 
12–18 12–25 12–18 12–25 
10 15 6.8 58.3 65.6 5.6 55.9 58.9 
 
25 2.2 8.2 25.6 1.3 5.4 16.1 
20 15 21.7 65.8 72.0 14.9 58.6 60.9 
 25 5.8 10.1 27.7 5.0 8.4 19.1 
*Table shows the projected reduction attributable to vaccination (%RAV) in HPV16 prevalence in populations with traditional and gender-similar 
age-specific sexual behavior after routine vaccination of 11-year-old girls only, with or without an additional 1-time catch-up (assumed coverage is 
70% for routine and catch-up vaccination). Two types of catch-up are considered (ages 12–18 and 12–25 years), along with 2 birth cohorts: women 
vaccinated at age 15 in both catch-up scenarios and women vaccinated at age 25 (only in the 12–25 catch-up scenario). The RAV was moderately 
larger in a population with a traditional sexual behavior than in a population with a gender-similar sexual behavior for all catch-up strategies 
investigated. After the first 10 (or 20) years after the introduction of vaccination, RAV of HPV16 prevalence was 66% (or 72%) among women 
vaccinated at 15 years of age in a population with a traditional age-specific sexual behavior and 59% (or 61%) in a population with a gender-similar 
age-specific sexual behavior. For women who were vaccinated at 25 years of age, the corresponding RAV 10 (or 20) years after vaccination was 
26% (or 28%) in a population with a traditional sexual behavior and 16% (or 19%) in a population with gender-similar sexual behavior. Results 
include indirect protection (herd immunity) from HPV16 infection in nonvaccinated women, as shown for vaccination without catch-up. 
 
 
Technical Appendix Figure 1. International correlation between average age difference (from man’s 
age to woman’s age) of spouses or cohabiting partners and the Human Development Index (HDI). 
Each circle is a country represented in a Demographic and Health Survey (1) and in the HDI (2). The 
average age difference between spouses or cohabiting partners ranged from 15 years in Burkina 
Faso to 2 years in Australia (specific countries not shown). The size of each circle is proportional to 
the size of the DHS survey. Age difference significantly decreases with improvements in a country’s 
HDI: man-to-woman age difference between spouses decreases linearly  by 1.25 years (95% CI 
16.5 to 8.4) for each 0.1 increase in the HDI (p value = 0.000). 
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Technical Appendix Figure 2. Comparison of model-based projections and HPV16 prevalence by 
age group in rural India (9) (panel A) and the United States (10) (panel B). Model projections were 
obtained by running the model with the parameters listed in Table 1 of main article. Assumed values 
were kept constant for both rural India and the United States, whereas calibrated values were specific 
for rural India and the United States (corresponding to heterosexual populations with traditional and 
gender-similar age-specific sexual behavior, respectively). 
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Technical Appendix Figure 3. Model-based age-specific HPV16 prevalence among women 20–34 
years of age by population type (i.e., whether a traditional population with a considerable age gap 
between spouses or a population with similar ages between spouses or cohabitating partners) and 
changes in HPV16 prevalence in relation to timing of transition in age-specific sexual behavior. For 
this sensitivity analysis, we changed the value of assortative mixing by sexual activity from 0.7, the 
calibrated value, to 0.3 (on a scale where fully and randomly assortative mixing correspond to values 
0 and 1, respectively). 
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Technical Appendix Figure 4. Model-based age-specific HPV16 prevalence among women 20–34 
years of age by vaccination status, population type (i.e. traditional population with a considerable age 
gap between spouses and a population with similar ages between spouses or cohabitating partners), 
and years since a traditional population transitioned (hypothetically) to a gender-similar population, 
assumptions previously described (12). Assumed average annual number of partners for both 
populations was 1.5 (panel A) and 2.0 (panel B). 
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